Skip to main content

Characteristics and outcomes of COVID-19 patients during the BA.5 omicron wave in Tehran, Iran: a prospective observational study

A Correction to this article was published on 07 August 2023

This article has been updated



Omicron (B.1.1.529) is the fifth variant of concern of SARS-CoV-2, which has several subvariants. Clinical features of BA.1 and BA.2 infections have been described in the literature, but we have limited information about the clinical profile of BA.5, which caused the seventh wave in Iran.


A prospective observational study was conducted on the BA.5 confirmed patients referred to Imam Khomeini Hospital Complex, Tehran, Iran, from 11th to 31st August 2022. The patients were divided into the two groups of outpatients and hospitalized patients, and their clinical, radiological, and laboratory data and outcomes were recorded and analyzed.


We included 193 patients with confirmed BA.5 infection, of whom 48 patients (24·8%) were hospitalized. The mean age of the patients was 45·3 ± 16·5 years, and 113 patients (58·5%) were female. The mean number of days patients had symptoms was 6·8 ± 2·4 days. The most common symptoms were weakness (69·9%), sore throat (67·4%), myalgia (66·3%), hoarseness (63·7%), headache (55·4%), fatigue (54·9%), and dry cough (50·3%). Fever and dyspnea were significantly more observed in the hospitalized patients (p < 0·0001). The COVID-19 vaccination rate was significantly lower in hospitalized patients than in outpatients (35/48–72·9% vs. 140/145 − 96·6%, p < 0·0001). The most common underlying diseases were hypertension (16·1%), diabetes mellitus (9·8%), and cardiovascular diseases (9·8%), all of which were significantly more common in hospitalized patients. Lung opacities were observed in 81·2% of hospitalized patients. By the end of our study, 1·5% of patients died despite receiving critical care services.


Our findings suggested that BA.5 symptoms are more non-respiratory and usually improve within 7 days. Although the proportion of hospitalized patients is still significant, very few patients require intensive care. COVID-19 vaccination is effective in reducing the hospitalization rate.

Trial registration

Not applicable. This study is not a clinical trial.

Peer Review reports


The Omicron (B.1.1.529) variant is the fifth variant of concern of SARS-CoV-2, which was first introduced in South Africa on November 25, 2021 and within a few days, caused a new wave of SARS-CoV-2 in South Africa and several other countries around the world [1, 2]. In South Africa, a higher and faster wave peak with less hospitalization, less severe illness, and ultimately fewer deaths than the previous waves were seen [3]. The reports from other countries also showed a reduced risk of severe disease in patients with the Omicron variant compared with the Delta variant [4,5,6,7]. The biological evidence suggests that Omicron has a lower virulence than the previous variants due to having different cellular entry mechanisms and preferential proliferation site in the respiratory tract tissue instead of the lung parenchyma [8]. It is unknown whether the SARS-CoV-2 previous infection and/or COVID-19 vaccination can provide protection against severe Omicron infection [9].

Among the dominant Omicron subvariants, BA.4 and BA.5, first isolated in South Africa in early 2022, are offshoots of Omicron BA.2 (despite BA.2 having fewer mutations than BA.1). These additional mutations in BA.4 and BA.5 seem to have associated them with a greater transmission potential [10, 11].

Previous studies show that patients with Omicron BA.2 were not associated with poorer outcomes than patients with BA.1 [12]. As the BA.5 subvariant emerged and became dominant, some reports showed increased hospitalization and even higher mortality [13,14,15].

Despite many reports on the characteristics of Omicron, more detailed epidemiological and clinical studies are required on this dominant variant and its emerging subvariants.[16].

In this study, we investigated the clinical symptoms, radiological features, laboratory characteristics, and outcomes of COVID-19 patients infected with the Omicron BA.5 subvariant in Tehran, Iran.


Study design and setting

A prospective observational study was conducted on the COVID-19 patients referred to Imam Khomeini Hospital Complex, Tehran, Iran, from August 11, 2022, to August 31, 2022, during the seventh wave (Omicron BA.5 wave).


All patients ≥ 12 years old with a positive SARS-CoV-2 test and confirmed Omicron BA.5 infection were included in the study. Patients with a positive SARS-CoV-2 test and confirmed Omicron BA.5 subvariant were identified and divided into two groups of hospitalized patients and outpatients.

SARS-CoV-2 variants identification

First, the nasopharyngeal samples from suspected COVID-19 patients were collected and transported to the hospital laboratory in falcons containing viral transport media (VTM). Then, the RNA extraction was conducted using the automated magnetic bead-based extractor (MagCore ®, RBC Bioscience, Taiwan) or the manual column-based kit (BehGene, Iran), following the virus inactivation in each sample. The extracted samples were placed in the freezer for further amplification and quantification by real-time polymerase chain reaction (RT-PCR) method using different kits, including Genova (USA), HanaGene (Iran), and COVITECH (Iran) and the detection system (CFX96, Bio-Rad, USA). All steps were performed according to the standard protocols of the kits.

Procedure and outcomes

The patients in each group were interviewed in person or by phone within 48 h of testing positive. The clinical information obtained regarding patients’ symptoms and conditions was recorded in data collection forms. The groups were then monitored for any laboratory tests and lung imaging ordered by patients’ clinicians. The research team did not intervene in the clinical and therapeutic management of the patients. The follow-up interview was performed on both groups seven days after the first interview. The outpatients were contacted by phone regarding the course of the disease, eventual hospitalization, and final consequences. Hospitalized patients were interviewed face-to-face regarding their vital signs, laboratory tests, and radiological signs in the chest CT scan. The clinical process and possible transfer to the intensive care unit or death were also recorded. The hospitalized patients were followed for two weeks after the first interview (Fig. 1).

Data analysis

We used descriptive statistics to analyze the details of clinical features, paraclinical characteristics, clinical course evidence, and death in the BA.5 patients during this time period. All patients who were still hospitalized and did not complete the two-weeks follow-up were excluded from the study. Analysis of laboratory tests was restricted to patients admitted to the hospital. The data were analyzed using the SPSS software version 20.0. The Mean and standard deviation (± SD) were used to display the quantitative data, and the frequency was used to display the qualitative data. The Chi-square analysis was used to compare qualitative variables between the groups of hospitalized and outpatients. The t-test analysis was also used to check the quantitative data between the two groups. An alpha level of less than 5% was considered significant.

Fig. 1
figure 1

Study design chart


After the evaluation of 207 patients with SARS-CoV-2 RT-PCR positive test, we included 193 patients with confirmed Omicron BA.5 infection in the study (48 (24·8%) hospitalized patients, and 145 (75.2%) outpatients). As seen in Table 1, the mean (± SD) age of the patients was 45·3 (± 16·5) years. One hundred thirteen patients (58·5%) were female, yet a significant proportion of hospitalized patients was male compared with the outpatients (56·3% vs. 36·6%, p < 0·0001). The mean (± SD) number of days patients had symptoms was 6·8 (± 2·4) days. The worst symptoms appeared on the third day (2·5 ± 1·1) from the disease onset in outpatients and on the second day (1·7 ± 0·9) in hospitalized patients (p < 0·0001).

Table 1 Baseline characteristics of patients with Omicron BA.5

As seen in Fig. 2, the most common baseline symptoms were weakness (69·9%), sore throat (67·4%), myalgia (66·3%), hoarseness (63·7%), headache (55·4%), fatigue (54·9%), and dry cough (50·3%). Dyspnea (27.6% vs. 60.4%, p < 0.0001) and fever (T > 38ºC) (13% vs. 29%, p = 0.01) were significantly more common in hospitalized patients than in outpatients (Fig. 3). None of our patients were asymptomatic.

Fig. 2
figure 2

The frequency of baseline clinical symptoms in Patients with Omicron BA.5

Fig. 3
figure 3

Comparison of baseline clinical symptoms of Omicron BA.5 between outpatients and hospitalized patients

In terms of the first visit vital signs, the mean (± SD) air room SpO2 was 93·9 (± 4·6%), and the mean (± SD) body temperature was 37·9 (± 1·0) ºC. Fever (T > 38ºc) was significantly more common in hospitalized patients than in outpatients (13% vs. 29%, p = 0·01).There were also significant differences between the two group in pulse rate, respiratory rate, and systolic blood pressure.

The most common underlying diseases were hypertension (16·1%), diabetes mellitus (9·8%), and ischemic heart diseases (9·8%), all of which were significantly more common in hospitalized patients (hypertension: 33·3%, ischemic heart diseases: 29.2%, diabetes mellitus: 27·1%) than in outpatients (87·5% vs. 33·1%, p < 0·0001).

Eighteen patients (9·3%) were unvaccinated for COVID-19, and the vaccination rate was significantly lower in hospitalized patients than in outpatients (35/48–72·9% vs. 140/145 − 96·6%, p < 0·0001). As seen in Fig. 4, of 133 patients receiving the last dose of the COVID-19 vaccine within three months before the BA.5 infection, 84·2% were outpatients and 15·8% were hospitalized, while of 10 patients receiving the last dose more than six months ago, 70% needed hospitalization (p < 0·0001).

Fig. 4
figure 4

Comparison of the last dose receiving time of COVID-19 vaccine between outpatients and hospitalized patients with Omicron BA.5

The results of paraclinical tests (Table 2), which were performed only for hospitalized patients, showed a high level of CRP (79·8 ± 56.8 mg/L). Among the 25·4% of patients who underwent CT scanning, lung opacity was observed in 39 patients (81·2%), and ground glass opacity was the most common pattern seen in 19 patients (39·6%).

Table 2 Baseline paraclinical features of hospitalized patients with BA.5 Omicron

In terms of the treatment regimen, 35 hospitalized patients (72·9%) were treated with remdesivir and 29 (60·4%) received dexamethasone. Outpatients did not receive any antiviral agents.

At the end of the study (day 14 for hospitalized patients), 13 patients (6·7%) were still hospitalized (none of them were in the ICU), and 3 hospitalized patients (1·5%) died despite receiving critical care services including mechanical ventilation.


We examined the clinical features and outcomes of SARS-CoV-2 infection among Iranian individuals with the Omicron BA.5 subvariant.

Although the average age of our patients was 45·3 years and none were asymptomatic, in a study on patients with BA.1 subvariant in China, the mean age was 34·5 years and 25% were asymptomatic [17]. In a review on Omicron BA.2 clinical studies, 58·1% of patients were found asymptomatic and only 4·2% experienced severe symptoms [18]. Our results suggest that the rate of symptomatic patients is probably higher in BA.5 infection than in previous Omicron subvariants infections.

Our findings also suggest that non-respiratory symptoms were the most common symptoms in patients with BA.5 Omicron infection, unlike in patients with COVID-19 caused by previous variants in whom respiratory symptoms were the most frequent symptoms [19, 20]. Similarly, in a study by Menni et al. on British patients with Omicron in late 2021, the most common clinical features were non-respiratory symptoms [21]. However, some symptoms such as weakness, myalgia, and hoarseness were more common in our study, sore throat was almost equally common in both studies, and sneezing and runny nose were clearly less common in our findings [21].

The most common symptom of patients with BA.5 Omicron subvariant in our study was weakness, and fever was less common (17·1%) than in a previous BA.1 Omicron report (32·8%). [17] However, fever was the most common symptom (> 80%) in early reports of the COVID-19 pandemic [19, 22, 23]. In our results, similar to the early COVID-19 results, cough was the most common respiratory symptom, and it was significantly more common in hospitalized patients with BA.5 Omicron [24].

The mean symptomatic period in patients with BA.5 infection in our study was about 7 days, which is consistent with the symptomatic days of early Omicron patients. This period was ten days in the reports before the Omicron wave [21, 25, 26]. It seems that Omicron and its subvariants cause a shorter symptomatic period than the previous SARS-CoV-2 variants. In previous studies, the most common underlying diseases associated with COVID-19 were hypertension, diabetes mellitus, and cardiovascular diseases, which were reported in the same order in our study [23, 27,28,29]. Hypertension and diabetes mellitus were similarly reported as the most common underlying diseases in patients with the BA.1 Omicron subvariant [17].

The rate of ICU admission and death in BA.5 hospitalized patients, which was reported low in our study and among individuals infected with earlier Omicron subvariants, is significantly lower than that in patients with pre-Omicron variants infections based on several large-scale studies [12, 30, 31].

The higher hospitalization rate among unvaccinated patients seen in our study confirms the COVID-19 vaccine effectiveness in reducing the risk of severe disease caused by any virus variant, including Omicron.[32,33,34]. The lower admission rate in patients during the Omicron wave can be explained by the combination of the lower virulence of Omicron and the immunity acquired from both vaccination and previous infections, so-called hybrid immunity [3, 35].

In terms of inflammatory markers, the CRP value was high in our BA.5 hospitalized patients, like in patients with other variants of SARS-CoV-2 [36,37,38]. However, compared with the reported CRP value for BA.1 and BA.2 in previous studies, the mean CRP level was higher in our study [17, 18]. The CRP level was reported to be significantly higher in patients with the Delta variant [19, 38].

Similar to reports from previous Omicron subvariants, ground glass opacity and bilateral involvement were the most common results of CT scan in our study [17, 39, 40].

The mortality rate in our BA.5 patients (1·5%), which was not associated with vaccination or any specific risk factor, seems to be lower than that in patients infected with the wild-type variant [19, 41, 42] and previous Omicron variants [5].

We were able to obtain useful clinical information about Omicron BA.5. However, since the data used in this study collected only from one hospital, the mortality group was too small to allow performing subgroup analyses. Another limitation of this study was the lack of sufficient information about the patients’ history of previous COVID-19 infections and its possible immunological effects on the symptoms, severity, and outcome of the current disease. There were also no laboratory results for outpatients because according to the national protocol for COVID-19 management, laboratory tests are requested only for hospitalized patients.


Our Findings suggest that BA.5 symptoms are more non-respiratory and usually improve within seven days. Although the proportion of hospitalized patients is still significant, very few patients require ICU admission. COVID-19 vaccination is effective in reducing the hospitalization rate in patients with BA.5.

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Change history



Severe acute respiratory syndrome coronavirus 2


Coronavirus disease 2019


C-reactive protein


Computed tomography


Intensive care unit


  1. Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021;398(10317):2126–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. 2022;603(7902):679–86.

  3. Jassat W, Abdool Karim SS, Mudara C, Welch R, Ozougwu L, Groome MJ, et al. Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. The Lancet Global Health. 2022;10(7):e961–e9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Jassat W, Karim S, Mudara C, Welch R, Ozougwu L, Groome M. Clinical severity of COVID-19 patients admitted to hospitals in Gauteng, South Africa during the Omicron-Dominant fourth wave. SSRN[Preprint]. 2021.

  5. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron Wave compared with previous waves. JAMA. 2022;327(6):583–4.

    Article  CAS  PubMed  Google Scholar 

  6. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. The Lancet. 2022;399(10323):437–46.

    Article  CAS  Google Scholar 

  7. Bhattacharyya RP, Hanage WP. Challenges in inferring intrinsic severity of the SARS-CoV-2 Omicron variant. N Engl J Med. 2022;386(7):e14.

    Article  CAS  PubMed  Google Scholar 

  8. Brown J, Zhou J, Peacock TP, Barclay WS. The SARS-CoV-2 Variant, Omicron, Shows Enhanced Replication in Human Primary Nasal Epithelial Cells. BioRxiv. 2022.

  9. Davies MA, Kassanjee R, Rosseau P, Morden E, Johnson L, Solomon W et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. medRxiv. 2022.

  10. Mahase E. Covid-19: What we know about the BA. 4 and BA. 5 omicron variants.bmj. 2022;378.

  11. Mahase E. Covid-19: What do we know about omicron sublineages? bmj. 2022;376.

  12. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes associated with SARS-CoV-2 Omicron (B. 1.1. 529) variant and BA. 1/BA. 1.1 or BA. 2 subvariant infection in southern California. Nature Medicine. 2022:1-.

  13. Poonia G. Omicron variants BA.4 and BA. 5 cause surge in deaths and cases in Portugal: Desert News; 2022 [Available from:

  14. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E et al. Continued emergence and evolution of Omicron in South Africa: New BA. 4 and BA. 5 lineages. medRxiv. 2022.

  15. Wise J. Covid-19: Omicron sub variants driving new wave of infections in UK. bmj. 2022;377(1506).

  16. Jansen L, Tegomoh B, Lange K, Showalter K, Figliomeni J, Abdalhamid B, et al. Investigation of a SARS-CoV-2 B. 1.1. 529 (omicron) variant cluster—Nebraska, November–December 2021. Morb Mortal Wkly Rep. 2021;70(51–52):1782.

    Article  CAS  Google Scholar 

  17. Gu B, Yao L, Zhu X-y, Zou T, Feng Y-j, Yan J-y, et al. Comparison of initial clinic characteristics of hospitalized patients in Suzhou City during the COVID-19 Omicron wave with ancestral variant wave. Ther Adv Respir Dis. 2022;16:17534666221110346.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Sahebi S, Keikha M. Clinical features of SARS-CoV-2 Omicron BA. 2; Lessons from previous observations–correspondence. Int J Surg (London England). 2022;104:106754.

    Article  Google Scholar 

  19. Allameh SF, Nemati S, Ghalehtaki R, Mohammadnejad E, Aghili SM, Khajavirad N et al. Clinical characteristics and outcomes of 905 COVID-19 patients admitted to Imam Khomeini hospital complex in the capital city of Tehran, Iran.Arch Iran Med. 2020:766–75.

  20. Chen X, Zheng F, Qing Y, Ding S, Yang D, Lei C et al. Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a double-center observational study. MedRxiv. 2020.

  21. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. The Lancet. 2022;399(10335):1618–24.

    Article  CAS  Google Scholar 

  22. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497–506.

    Article  CAS  Google Scholar 

  23. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Siordia JA Jr. Epidemiology and clinical features of COVID-19: a review of current literature. J Clin Virol. 2020;127:104357.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Wang L, Gao Y-h, Zhang LL-L. G-J. The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China. European Respiratory Journal. 2020;55(4).

  26. Wise J. Covid-19: Symptomatic infection with omicron variant is milder and shorter than with delta, study reports. BMJ: British Medical Journal (Online). 2022;377.

  27. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x et al. Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv. 2020.

  28. Ma C, Gu J, Hou P, Zhang L, Bai Y, Guo Z, et al. Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis. medRxiv; 2020.

  29. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Bager P, Wohlfahrt J, Bhatt S, Stegger M, Legarth R, Møller CH, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study. The Lancet Infectious Diseases; 2022.

  31. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: a cohort study. The Lancet. 2022;399(10332):1303–12.

    Article  CAS  Google Scholar 

  32. Abdool Karim SS, de Oliveira T. New SARS-CoV-2 variants—clinical, public health, and vaccine implications. N Engl J Med. 2021;384(19):1866–8.

    Article  PubMed  Google Scholar 

  33. Collie S, Champion J, Moultrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2 vaccine against omicron variant in South Africa. N Engl J Med. 2022;386(5):494–6.

    Article  PubMed  Google Scholar 

  34. Rosenberg ES, Dorabawila V, Easton D, Bauer UE, Kumar J, Hoen R, et al. Covid-19 vaccine effectiveness in New York State. N Engl J Med. 2021;386(2):116–27.

    Article  PubMed  Google Scholar 

  35. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063.

    Article  CAS  PubMed  Google Scholar 

  36. Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob. 2020;19(1):1–7.

    Article  CAS  Google Scholar 

  37. Ghazanfari T, Salehi MR, Namaki S, Arabkheradmand J, Rostamian A, Rajabnia Chenary M, et al. Interpretation of hematological, biochemical, and immunological findings of COVID-19 Disease: biomarkers Associated with Severity and Mortality. Iran J Allergy Asthma Immunol. 2021;20(1):46–66.

    PubMed  Google Scholar 

  38. Suzuki K, Ichikawa T, Suzuki S, Tanino Y, Kakinoki Y. Clinical characteristics of the severe acute respiratory syndrome coronavirus 2 omicron variant compared with the delta variant: a retrospective case-control study of 318 outpatients from a single sight institute in Japan. PeerJ. 2022;10:e13762.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Bi X, Zhang Y, Pan J, Chen C, Zheng Y, Wang J et al. Differences Between Omicron Infections and Fever Outpatients: Comparison of Clinical Manifestations and Initial Routine Hematology Indicators. Infection and Drug Resistance. 2022:5111–20.

  40. Tsakok MT, Watson RA, Saujani SJ, Kong M, Xie C, Peschl H et al. Chest CT and Hospital Outcomes in Patients with Omicron Compared with Delta Variant SARS-CoV-2 Infection. Radiology. 2022:220533.

  41. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020;20(7):773.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Jain VK, Iyengar K, Vaish A, Vaishya R. Differential mortality in COVID-19 patients from India and western countries. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(5):1037–41.

    Article  Google Scholar 

Download references


We would like to thank Mrs. Fariba Zamani, MSc, ELS, for the language editing of this manuscript. We also thank the Iranian Research Center for HIV/AIDS for all their help and the dedicated staff at Imam Khomeini Hospital Complex.


The authors received no funding or financial support for this study.

Author information

Authors and Affiliations



MS contributed to conceptualization and interpretation. ASK, AS, RF, and KF contributed to data collection. ASK and MA contributed to the writing of the original draft. MD, EM and, AS contributed to the methodology design. MA and AA contributed to data validation. MD contributed to project administration. AA supervised the diagnostic laboratory methods of the Omicron subvariants. EM supervised the clinical data gathering. JZ contributed to software and formal analysis. ASF contributed to writing, reviewing, and editing. ASF, as the corresponding author, had full access to all parts of the study and had the responsibility of submitting the manuscript for publication.

Corresponding author

Correspondence to Abbas Shakoori Farahani.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the ethics committee of Tehran University of Medical Sciences, Tehran, Iran (No: IR.TUMS.MEDICINE.REC.1401.554). All methods were carried out in accordance with relevant guidelines and regulations. This study was conducted in an academic teaching/research hospital (Imam Khomeini Hospital Complex affiliated to Tehran University of Medical Sciences). In this academic center, all patients or their legal guardians are initially explained that their information and possible samples will be anonymously collected and reviewed and reported in educational and research projects. The patients who give written consent to this issue will be included in the mentioned studies (like our study). Patients are allowed to freely choose whether or not their data be used in an anonymized database. This is also stated in the ethics committee approval. Informed consent was obtained from all the patients and/or their legal guardian(s) for this study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article has been updated to correct an author name.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Salehi, M., Salami Khaneshan, A., Farahani, A.S. et al. Characteristics and outcomes of COVID-19 patients during the BA.5 omicron wave in Tehran, Iran: a prospective observational study. BMC Infect Dis 23, 237 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Clinical characteristics
  • Iran
  • Omicron BA.5
  • COVID-19